Sawai Pharmaceutical Co Ltd (Sawai Pharmaceutical) manufactures, sells, imports and exports ethical drugs and proprietary drugs. The company's products include cardiovascular drugs, antihyperlipidemic agents, diabetes drugs, anticancer drugs and OTC drugs. It provides products in the form of tablets, oral dispersing tablets, capsules, granule, injection, tape, ophthalmic and nasal solution and syrup. Sawai Pharmaceutical caters to hospitals, general practitioners and dispensing pharmacies. The company has manufacturing facilities in Kanto, Kashima, Osaka, Daini, Sanda and Kyusyu. It has its presence in Sapporo, Tokyo Daiichi, Sendai, Kitakanto, Tokyo Daini, Nagoya, Osaka, Hiroshima and Fukuoka. Sawai Pharmaceutical is headquartered in Osaka, Japan.
Headquarters
Japan
Address
5-2-30 Miyahara, Yodogawa-Ku, Osaka, Osaka, 532-0003
Website
www.sawai.co.jp
Telephone
81 6 6105 5711
No of Employees
2,414
Industry
Pharmaceuticals and Healthcare
Explore premium data & analytics
Products and Services
| Products |
|---|
| Cardiovascular Drugs |
| Antihyperlipidemic Agents |
| Diabetes Drugs |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | New Products/Services | In June, the company launched eight generic drugs with 23 strengths leading its product line to comprise of 327 compounds with 808 strengths |
| 2021 | Contracts/Agreements | In January, the company and Neurolief Ltd entered into an exclusive agreement to develop Relivion, a non-invasive digital medical device for migraine and depression, in Japan. |
| 2020 | New Products/Services | In December, the company's subsidiary, Upsher-Smith Laboratories announced the launch of Ramelteon Tablets, 8 mg to treat insomnia characterized by difficulty with sleep onset. |
Competitor Comparison
| Key Parameters | Sawai Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | COSMOS Pharmaceutical Corp | Sumitomo Pharma Co Ltd | ASKA Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka, Osaka | Chuo-Ku | Fukuoka-Shi | Osaka-Shi | Minato-Ku |
| State/Province | - | Tokyo | Fukuoka | Osaka | Tokyo |
| No. of Employees | 2,414 | 7,664 | 4,872 | 6,822 | 807 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mitsuo Sawai | Chief Executive Officer; Chairman - Group; Representative Director | Executive Board | 2021 | 65 |
| Kenzo Sawai | Representative Director; Chief Brand Officer; Group Deputy Chairman | Executive Board | 2021 | 53 |
| Kazuhiko Sueyoshi | President; Supervisor of Corporate Strategy | Executive Board | 2021 | 64 |
| Toru Terashima | Director; Group Chief Quality & Safety Officer | Executive Board | 2021 | 62 |
| Akira Hamada | Group Chief Human Resource Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer